726. Clinical Trial of Recombinant Adenovirus-p53 (Gendicine) Combined with Radiotherapy in Nasopharyngeal Carcinoma Patients

Shanwen Zhang(King University), Bo Xu(Chengdu University of Traditional Chinese Medicine), Xing Su(King University), Changqing Liu(Shanghai Innovative Research Center of Traditional Chinese Medicine), Dongming Li(Dalian University), Shaowen Xiao(Jiangxi Provincial Cancer Hospital), Gang Xu(Harbin Medical University), Guangying Zhu(Jilin University), Yan Sun(Peking University)
Molecular Therapy
January 1, 2006
10.1016/j.ymthe.2006.08.806
Cited by 4

Related Papers

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Association of Cerebral Deficits With Clinical Symptoms in Antipsychotic-Naive First-Episode Schizophrenia: An Optimized Voxel-Based Morphometry and Resting State Functional Connectivity Study
|American Journal of Psychiatry|2008|257
Fabrication and Electrochemical Treatment Application of A Novel Lead Dioxide Anode with Superhydrophobic Surfaces, High Oxygen Evolution Potential, and Oxidation Capability
|Environmental Science & Technology|2010|237
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
|The Lancet|2021|234